메뉴 건너뛰기




Volumn 42, Issue 4, 2014, Pages

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; CD63 ANTIGEN; DACTOLISIB; DASATINIB; EOTAXIN; ERLOTINIB; EVEROLIMUS; FIP1L1 PDGFRA PROTEIN; GEFITINIB; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; LAPATINIB; MASITINIB; MIDOSTAURIN; NILOTINIB; ONCOPROTEIN; PICEATANNOL; PIMOZIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; PROTEIN KINASE B; S6 KINASE; SORAFENIB; STAT5 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; TOZASERTIB; UNCLASSIFIED DRUG; VORINOSTAT;

EID: 84899110892     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.12.007     Document Type: Article
Times cited : (40)

References (37)
  • 1
    • 21344440247 scopus 로고    scopus 로고
    • Molecular classification and pathogenesis of eosinophilic disorders: 2005 update
    • Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 2005, 114:7-25.
    • (2005) Acta Haematol , vol.114 , pp. 7-25
    • Gotlib, J.1
  • 2
    • 33646245681 scopus 로고    scopus 로고
    • Eosinophilia: secondary, clonal and idiopathic
    • Tefferi A., Patnaik M.M., Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006, 133:468-492.
    • (2006) Br J Haematol , vol.133 , pp. 468-492
    • Tefferi, A.1    Patnaik, M.M.2    Pardanani, A.3
  • 3
    • 34548525771 scopus 로고    scopus 로고
    • Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome
    • Bain B.J., Fletcher S.H. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007, 27:377-388.
    • (2007) Immunol Allergy Clin North Am , vol.27 , pp. 377-388
    • Bain, B.J.1    Fletcher, S.H.2
  • 4
    • 84892809487 scopus 로고    scopus 로고
    • Chronic eosinophilic leukemia/hypereosinophilic syndrome
    • Gotlib J. Chronic eosinophilic leukemia/hypereosinophilic syndrome. Cancer Treat Res 2008, 142:69-106.
    • (2008) Cancer Treat Res , vol.142 , pp. 69-106
    • Gotlib, J.1
  • 5
    • 67349151349 scopus 로고    scopus 로고
    • Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders
    • Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 2009, 23:157-165.
    • (2009) Blood Rev , vol.23 , pp. 157-165
    • Valent, P.1
  • 6
    • 0344987881 scopus 로고    scopus 로고
    • A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
    • Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
    • (2003) N Engl J Med , vol.348 , pp. 1201-1214
    • Cools, J.1    DeAngelo, D.J.2    Gotlib, J.3
  • 7
    • 1842474941 scopus 로고    scopus 로고
    • The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
    • Gotlib J., Cools J., Malone J.M., et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004, 103:2879-2891.
    • (2004) Blood , vol.103 , pp. 2879-2891
    • Gotlib, J.1    Cools, J.2    Malone, J.M.3
  • 10
    • 0037596569 scopus 로고    scopus 로고
    • Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
    • Griffin J.H., Leung J., Bruner R.J., et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003, 100:7830-7835.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 7830-7835
    • Griffin, J.H.1    Leung, J.2    Bruner, R.J.3
  • 11
    • 1642324059 scopus 로고    scopus 로고
    • The EOL-1 cell line as an invitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    • Cools J., Quentmeier H., Huntly B.J., et al. The EOL-1 cell line as an invitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004, 103:2802-2805.
    • (2004) Blood , vol.103 , pp. 2802-2805
    • Cools, J.1    Quentmeier, H.2    Huntly, B.J.3
  • 12
    • 33749983643 scopus 로고    scopus 로고
    • Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells
    • Verstovsek S., Giles F.J., Quintás-Cardama A., et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 2006, 30:1499-1505.
    • (2006) Leuk Res , vol.30 , pp. 1499-1505
    • Verstovsek, S.1    Giles, F.J.2    Quintás-Cardama, A.3
  • 13
    • 38949217352 scopus 로고    scopus 로고
    • All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line
    • Robert C., Apàti A., Chomienne C., et al. All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line. Leuk Res 2008, 32:343-346.
    • (2008) Leuk Res , vol.32 , pp. 343-346
    • Robert, C.1    Apàti, A.2    Chomienne, C.3
  • 14
    • 52049122130 scopus 로고    scopus 로고
    • Dasatinib inhibits thegrowth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha
    • Baumgartner C., Gleixner K.V., Peter B., et al. Dasatinib inhibits thegrowth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008, 36:1244-1253.
    • (2008) Exp Hematol , vol.36 , pp. 1244-1253
    • Baumgartner, C.1    Gleixner, K.V.2    Peter, B.3
  • 15
    • 84856832061 scopus 로고    scopus 로고
    • Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model
    • Wicklein D., Ramos Leal N., Salamon J., et al. Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLoS One 2012, 7:e30567.
    • (2012) PLoS One , vol.7
    • Wicklein, D.1    Ramos Leal, N.2    Salamon, J.3
  • 16
    • 0038386031 scopus 로고    scopus 로고
    • Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
    • Pardanani A., Reeder T., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003, 101:3391-3397.
    • (2003) Blood , vol.101 , pp. 3391-3397
    • Pardanani, A.1    Reeder, T.2    Porrata, L.F.3
  • 17
    • 34249732053 scopus 로고    scopus 로고
    • Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    • Jovanovic J.V., Score J., Waghorn K., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635-4640.
    • (2007) Blood , vol.109 , pp. 4635-4640
    • Jovanovic, J.V.1    Score, J.2    Waghorn, K.3
  • 18
    • 35348993411 scopus 로고    scopus 로고
    • The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    • Baccarani M., Cilloni D., Rondoni M., et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92:1173-1179.
    • (2007) Haematologica , vol.92 , pp. 1173-1179
    • Baccarani, M.1    Cilloni, D.2    Rondoni, M.3
  • 19
    • 55949102355 scopus 로고    scopus 로고
    • Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
    • Metzgeroth G., Walz C., Erben P., et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008, 143:707-715.
    • (2008) Br J Haematol , vol.143 , pp. 707-715
    • Metzgeroth, G.1    Walz, C.2    Erben, P.3
  • 20
    • 0346249716 scopus 로고    scopus 로고
    • The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia
    • Cools J., Stover E.H., Wlodarska I., et al. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004, 11:51-57.
    • (2004) Curr Opin Hematol , vol.11 , pp. 51-57
    • Cools, J.1    Stover, E.H.2    Wlodarska, I.3
  • 21
    • 66849087150 scopus 로고    scopus 로고
    • FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib
    • Lierman E., Michaux L., Beullens E., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
    • (2009) Leukemia , vol.23 , pp. 845-851
    • Lierman, E.1    Michaux, L.2    Beullens, E.3
  • 22
    • 65549100146 scopus 로고    scopus 로고
    • A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome
    • Salemi S., Yousefi S., Simon D., et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 2009, 64:913-918.
    • (2009) Allergy , vol.64 , pp. 913-918
    • Salemi, S.1    Yousefi, S.2    Simon, D.3
  • 23
    • 79952004905 scopus 로고    scopus 로고
    • The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations invitro
    • von Bubnoff N., Gorantla S.P., Engh R.A., et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations invitro. Oncogene 2011, 30:933-943.
    • (2011) Oncogene , vol.30 , pp. 933-943
    • von Bubnoff, N.1    Gorantla, S.P.2    Engh, R.A.3
  • 24
    • 0142119964 scopus 로고    scopus 로고
    • PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
    • Cools J., Stover E.H., Boulton C.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003, 3:459-469.
    • (2003) Cancer Cell , vol.3 , pp. 459-469
    • Cools, J.1    Stover, E.H.2    Boulton, C.L.3
  • 25
    • 33747203008 scopus 로고    scopus 로고
    • Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant
    • Lierman E., Folens C., Stover E.H., et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108:1374-1376.
    • (2006) Blood , vol.108 , pp. 1374-1376
    • Lierman, E.1    Folens, C.2    Stover, E.H.3
  • 26
    • 33745059630 scopus 로고    scopus 로고
    • The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)
    • von Bubnoff N., Gorantla S.P., Thöne S., et al. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006, 107:4970-4971.
    • (2006) Blood , vol.107 , pp. 4970-4971
    • von Bubnoff, N.1    Gorantla, S.P.2    Thöne, S.3
  • 27
    • 84863782614 scopus 로고    scopus 로고
    • Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases
    • Lierman E., Smits S., Cools J., et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 2012, 26:1693-1695.
    • (2012) Leukemia , vol.26 , pp. 1693-1695
    • Lierman, E.1    Smits, S.2    Cools, J.3
  • 28
    • 0022360099 scopus 로고
    • Establishment and characterization of a new human eosinophilic leukemia cell line
    • Saito H., Bourinbaiar A., Ginsburg M., et al. Establishment and characterization of a new human eosinophilic leukemia cell line. Blood 1985, 66:1233-1240.
    • (1985) Blood , vol.66 , pp. 1233-1240
    • Saito, H.1    Bourinbaiar, A.2    Ginsburg, M.3
  • 29
    • 0032530972 scopus 로고    scopus 로고
    • Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes
    • Schwaller J., Frantsve J., Aster J., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998, 17:5321-5333.
    • (1998) EMBO J , vol.17 , pp. 5321-5333
    • Schwaller, J.1    Frantsve, J.2    Aster, J.3
  • 30
    • 0036373335 scopus 로고    scopus 로고
    • Morphological and biochemical aspects of apoptosis, oncosis and necrosis
    • Van Cruchten S., Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002, 31:214-223.
    • (2002) Anat Histol Embryol , vol.31 , pp. 214-223
    • Van Cruchten, S.1    Van Den Broeck, W.2
  • 31
    • 84856396314 scopus 로고    scopus 로고
    • The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils
    • Blatt K., Herrmann H., Mirkina I., et al. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One 2012, 7:e29925.
    • (2012) PLoS One , vol.7
    • Blatt, K.1    Herrmann, H.2    Mirkina, I.3
  • 32
    • 84862024642 scopus 로고    scopus 로고
    • NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation
    • Hadzijusufovic E., Peter B., Herrmann H., et al. NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy 2012, 67:858-868.
    • (2012) Allergy , vol.67 , pp. 858-868
    • Hadzijusufovic, E.1    Peter, B.2    Herrmann, H.3
  • 33
    • 0024323740 scopus 로고
    • Recombinant human interleukin 5 is a selective eosinophil chemoattractant
    • Wang J.M., Rambaldi A., Biondi A., et al. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989, 19:701-705.
    • (1989) Eur J Immunol , vol.19 , pp. 701-705
    • Wang, J.M.1    Rambaldi, A.2    Biondi, A.3
  • 34
    • 0029836124 scopus 로고    scopus 로고
    • Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice
    • Rothenberg M.E., Ownbey R., Mehlhop P.D., et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 1996, 2:334-348.
    • (1996) Mol Med , vol.2 , pp. 334-348
    • Rothenberg, M.E.1    Ownbey, R.2    Mehlhop, P.D.3
  • 35
    • 84878089990 scopus 로고    scopus 로고
    • Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia
    • Hoermann G., Cerny-Reiterer S., Sadovnik I., et al. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. Allergy 2013, 68:713-723.
    • (2013) Allergy , vol.68 , pp. 713-723
    • Hoermann, G.1    Cerny-Reiterer, S.2    Sadovnik, I.3
  • 36
    • 84863805992 scopus 로고    scopus 로고
    • Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field
    • Valent P., Gleich G.J., Reiter A., et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012, 5:157-176.
    • (2012) Expert Rev Hematol , vol.5 , pp. 157-176
    • Valent, P.1    Gleich, G.J.2    Reiter, A.3
  • 37
    • 84870012939 scopus 로고    scopus 로고
    • Ponatinib in refractory Philadelphia chromosome-positive leukemias
    • Cortes J.E., Kantarjian H., Shah N.P., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367:2075-2088.
    • (2012) N Engl J Med , vol.367 , pp. 2075-2088
    • Cortes, J.E.1    Kantarjian, H.2    Shah, N.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.